High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

(2019) Ilaria Saltarella et al.   Journal of Hematology & Oncology

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients

(2019) John R. Jones et al.   HAEMATOLOGICA

Future of personalized therapy targeting aberrant signaling pathways in multiple myeloma

(2019) Faiz Anwer et al.   Clinical Lymphoma Myeloma & Leukemia

The bone marrow microenvironment at single-cell resolution

(2019) Anastasia N. Tikhonova et al.   NATURE

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma

(2018) Vanessa Desantis et al.   ANNALS OF HEMATOLOGY

Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network

(2018) Patrizia Zappasodi et al.   ANNALS OF HEMATOLOGY

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

(2018) Leo Rasche et al.   BLOOD

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

(2018) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial

(2018) Angelo Vacca et al.   CLINICAL IMMUNOLOGY

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

Spectrum and functional validation of PSMB5 mutations in multiple myeloma

(2018) Santiago Barrio et al.   LEUKEMIA

The bone-marrow niche in MDS and MGUS: implications for AML and MM

(2018) Irene M. Ghobrial et al.   Nature Reviews Clinical Oncology

Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma

(2018) Roberta Ettari et al.   PHARMACOLOGY & THERAPEUTICS

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma

(2018) Takashi Yoshida et al.   PLoS One

Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods

(2018) Neeta Pandit-Taskar   SEMINARS IN HEMATOLOGY

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma

(2018) Aurelia Lamanuzzi et al.   Oncotarget

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study

(2018) Luigia Rao et al.   Oncotarget

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

(2018) Niels W.C.J. van de Donk et al.   Frontiers in Immunology

Hexokinase-2 Expression in MET-positive FDG-negative Multiple Myeloma

(2018) Stefan Kircher et al.   JOURNAL OF NUCLEAR MEDICINE

Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes

(2018) Maria Antonia Frassanito et al.   JOURNAL OF PATHOLOGY

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma

(2018) L. Rasche et al.   LEUKEMIA

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

(2018) Guy Ledergor et al.   NATURE MEDICINE

EMT Transition States during Tumor Progression and Metastasis

(2018) Ievgenia Pastushenko et al.   TRENDS IN CELL BIOLOGY

Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses

(2018) Qiumei Yao et al.   Clinical Epigenetics

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

(2018) Laurie Herviou et al.   Clinical Epigenetics

Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients

(2018) Patrizia Leone et al.   OncoImmunology

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

(2017) Tania Díaz et al.   HAEMATOLOGICA

Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage

(2017) Travis Nemkov et al.   HAEMATOLOGICA

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment

(2017) Martina Rudelius et al.   HAEMATOLOGICA

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

(2017) Juan-Jose Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomics of Multiple Myeloma

(2017) Sebastien Robiou du Pont et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

(2017) Michele Cavo et al.   LANCET ONCOLOGY

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma

(2017) A G Solimando et al.   LEUKEMIA

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

(2017) N Bolli et al.   LEUKEMIA

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

(2017) A Natoni et al.   LEUKEMIA

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

(2017) J Martinez-Lopez et al.   LEUKEMIA

CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma

(2017) Chang-Xin Shi et al.   MOLECULAR CANCER THERAPEUTICS

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

(2017) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer

(2017) Shuxia Li et al.   Oncology Letters

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

(2017) L. Rasche et al.   Nature Communications

MRD in multiple myeloma: more questions than answers?

(2017) Philippe Moreau et al.   Blood Cancer Journal

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma

(2017) Elina Alaterre et al.   Oncotarget

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma

(2017) Constantin Lapa et al.   Theranostics

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values

(2017) Constantin Lapa et al.   Theranostics

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

(2017) Tania Díaz et al.   HAEMATOLOGICA

Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage

(2017) Travis Nemkov et al.   HAEMATOLOGICA

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment

(2017) Martina Rudelius et al.   HAEMATOLOGICA

Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management

(2016) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

(2016) Artur Jurczyszyn et al.   AMERICAN JOURNAL OF HEMATOLOGY

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

(2016) K. M. Kortum et al.   BLOOD

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

(2016) M. S. Raab et al.   BLOOD

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

(2016) Xing-Ding Zhang et al.   CANCER CELL

Primary Plasma Cell Leukemia: Identity Card 2016

(2016) Pellegrino Musto et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Emerging antibodies for the treatment of multiple myeloma

(2016) Flora Zagouri et al.   EXPERT OPINION ON EMERGING DRUGS

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

(2016) J Krönke et al.   LEUKEMIA

Trends in overall survival and costs of multiple myeloma, 2000–2014

(2016) R Fonseca et al.   LEUKEMIA

Targeting vasculogenesis to prevent progression in multiple myeloma

(2016) M Moschetta et al.   LEUKEMIA

Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

(2016) Ruth Eichner et al.   NATURE MEDICINE

Genomic complexity of multiple myeloma and its clinical implications

(2016) Salomon Manier et al.   Nature Reviews Clinical Oncology

Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines

(2016) Cong Wang et al.   Targeted Oncology

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

(2016) K M Kortuem et al.   Blood Cancer Journal

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

(2016) Y Jethava et al.   Blood Cancer Journal

Microenvironment drug resistance in multiple myeloma: emerging new players

(2016) Lucia Di Marzo et al.   Oncotarget

11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement

(2016) Constantin Lapa et al.   Theranostics

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome

(2015) Marzia Varettoni et al.   AMERICAN JOURNAL OF HEMATOLOGY

Dual role of fatty acid-binding protein 5 on endothelial cell fate: a potential link between lipid metabolism and angiogenic responses

(2015) Chen-Wei Yu et al.   ANGIOGENESIS

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

(2015) M.-L. Chretien et al.   BLOOD

How I treat extramedullary myeloma

(2015) C. Touzeau et al.   BLOOD

New criteria for response assessment: role of minimal residual disease in multiple myeloma

(2015) B. Paiva et al.   BLOOD

SnapShot: Multiple Myeloma

(2015) Esteban Braggio et al.   CANCER CELL

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

(2015) B. Holkova et al.   CLINICAL CANCER RESEARCH

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

(2015) Christof Scheid et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

(2015) R. M. de Tute et al.   HAEMATOLOGICA

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibiting MEK in MAPK pathway-activated myeloma

(2015) C J Heuck et al.   LEUKEMIA

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

(2015) A K Mitra et al.   LEUKEMIA

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

(2015) Ruben Niesvizky et al.   LEUKEMIA & LYMPHOMA

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

(2015) E H Rustad et al.   Blood Cancer Journal

Interpretation of cytogenetic results in multiple myeloma for clinical practice

(2015) A M Rajan et al.   Blood Cancer Journal

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus

(2015) Kevin R. Kelly et al.   Oncotarget

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation

(2015) Aldo M. Roccaro et al.   Cell Reports

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

(2015) Barbara Muz et al.   Biomed Research International

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

(2015) R. M. de Tute et al.   HAEMATOLOGICA

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells

(2015) Daniele Tibullo et al.   Frontiers in Pharmacology

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma

(2014) J. Kummetha Venkata et al.   BLOOD

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

(2014) Y. X. Zhu et al.   BLOOD

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target

(2014) A. Ferrucci et al.   CLINICAL CANCER RESEARCH

Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis

(2014) Sylwia Łopuch et al.   Hematology

Targeting the bone marrow microenvironment in multiple myeloma

(2014) Yawara Kawano et al.   IMMUNOLOGICAL REVIEWS

Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death

(2014) Philippe Moreau et al.   JOURNAL OF CLINICAL ONCOLOGY

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

(2014) Gordon Cook et al.   LANCET ONCOLOGY

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

(2014) L Melchor et al.   LEUKEMIA

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies

(2014) O. Abdel-Wahab et al.   Cancer Discovery

Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease

(2013) Jan B. Egan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma

(2013) M. Moschetta et al.   CLINICAL CANCER RESEARCH

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

(2013) L. Pour et al.   HAEMATOLOGICA

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

(2013) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

(2013) C C Bjorklund et al.   LEUKEMIA

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

(2013) M Offidani et al.   Blood Cancer Journal

Targeting the BRAF V600E Mutation in Multiple Myeloma

(2013) M. Andrulis et al.   Cancer Discovery

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma

(2012) B. A. Walker et al.   BLOOD

How I treat plasma cell leukemia

(2012) N. W. C. J. van de Donk et al.   BLOOD

Myeloma as a model for the process of metastasis: implications for therapy

(2012) I. M. Ghobrial   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

(2012) M. Faham et al.   BLOOD

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

(2012) S. Z. Usmani et al.   HAEMATOLOGICA

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

A gene expression signature for high-risk multiple myeloma

(2012) R Kuiper et al.   LEUKEMIA

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

(2012) C Fernández de Larrea et al.   LEUKEMIA

BRAF Inhibition in Refractory Hairy-Cell Leukemia

(2012) Sascha Dietrich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma

(2012) Roberto Ria et al.   Stem Cells International

Integrin  7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

(2011) P. Neri et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

(2011) E. Zamagni et al.   BLOOD

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

(2011) Klaus Podar et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells

(2011) L. Lopez-Corral et al.   CLINICAL CANCER RESEARCH

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

(2011) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

(2011) K D Boyd et al.   LEUKEMIA

Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets

(2011) S Berardi et al.   ONCOGENE

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

(2010) F. van Rhee et al.   BLOOD

Angiogenesis Inhibitors: Current Strategies and Future Prospects

(2010) K. M. Cook et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling

(2010) Gemma Migneco et al.   CELL CYCLE

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

(2010) K. Neben et al.   HAEMATOLOGICA

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy

(2010) Valéria C. C. Andrade et al.   LEUKEMIA & LYMPHOMA

Adhesion molecules—The lifelines of multiple myeloma cells

(2010) Ben-Zion Katz   SEMINARS IN CANCER BIOLOGY

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

(2009) M. Varettoni et al.   ANNALS OF ONCOLOGY

Induction of angiogenesis by normal and malignant plasma cells

(2009) D. Hose et al.   BLOOD

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

(2008) B. Barlogie et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

(2008) Bart Barlogie et al.   CANCER

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

(2008) M. B. Meads et al.   CLINICAL CANCER RESEARCH

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

(2008) Olivier Decaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

(2008) Juan José Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE